LG Chem (051910) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
4 May, 2026Executive summary
Q1 2026 consolidated revenue reached KRW 12.247 trillion, a 6.2% increase from Q4 2025 but down 2.6% year-over-year, with an operating loss of KRW 50 billion and a net loss of KRW 782 billion, narrowing from the previous quarter.
Total assets were KRW 105.7 trillion, liabilities KRW 57.6 trillion, and equity KRW 48 trillion.
The debt to equity ratio increased to 119.7% sequentially.
Market volatility and demand uncertainty persist due to geopolitical risks and weak North American EV demand.
Financial highlights
Q1 consolidated revenue: KRW 12.247 trillion; operating loss: KRW 50 billion; net loss: KRW 782 billion.
Gross margin for Q1 2026 was 18.9%, up from 15.9% in Q4 2025 but down from 19.9% in 2025.
EBITDA for Q1 2026 was KRW 1,442 billion, up from KRW 1,103 billion in Q4 2025.
Cash and equivalents at quarter-end were KRW 9,685 billion, down from KRW 10,903 billion at Q4 2025.
Positive inventory lagging effects and one-off income from European anti-dumping duty refunds supported petrochemical profitability.
Outlook and guidance
Persistent market volatility expected due to Middle East conflict and North American EV demand softness.
Petrochemicals profitability expected to remain stable QoQ despite reduced sales from a temporary NCC No.2 shutdown, supported by naphtha lag effects and cost reductions.
Advanced Materials projected to turn profitable, driven by increased cathode material volumes.
Life Sciences anticipates revenue growth from higher volumes and ongoing global clinical R&D investments.
Energy Solution expects revenue growth from expanded ESS shipments and stable cylindrical EV battery demand.
Disciplined CapEx execution under KRW 2 trillion annually, portfolio rebalancing, and asset monetization planned.
Latest events from LG Chem
- Q3 profit rebounded on Energy Solution gains, but outlook remains cautious amid market headwinds.051910
Q3 202428 May 2026 - Q2 sales and profit rose, but net income and guidance fell amid weak EV demand and higher costs.051910
Q2 202428 May 2026 - Lower 2024 profits and weak demand drive restructuring, cost control, and cautious investment.051910
Q4 202428 May 2026 - Accelerating growth in sustainability, battery materials, and new drugs to drive future value.051910
Corporate presentation20 May 2026 - Four growth drivers are set to triple their revenue share by 2030 through strategic restructuring.051910
Corporate presentation20 May 2026 - Driving global sustainability and innovation with advanced materials and life sciences.051910
Corporate presentation20 May 2026 - 2025 saw a net loss and restructuring, with 2026 focused on growth and portfolio optimization.051910
Q4 202522 Apr 2026 - Operating profit improved in Q2 2025, but sales fell and net income turned negative.051910
Q2 20253 Feb 2026 - Profitability rebounded in Q1 2025 amid volatility, driven by cost controls and segment recovery.051910
Q1 20257 Jan 2026